- Home
- BMBL vs STOK Comparison
BMBL vs STOK Comparison
Compare BMBL & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- STOK
- Stock Information
- Founded
- BMBL 2014
- STOK 2014
- Country
- BMBL United States
- STOK United States
- Employees
- BMBL N/A
- STOK N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- STOK Health Care
- Exchange
- BMBL Nasdaq
- STOK Nasdaq
- Market Cap
- BMBL 446.5M
- STOK 517.0M
- IPO Year
- BMBL 2021
- STOK 2019
- Fundamental
- Price
- BMBL $5.74
- STOK $9.91
- Analyst Decision
- BMBL Hold
- STOK Strong Buy
- Analyst Count
- BMBL 15
- STOK 5
- Target Price
- BMBL $6.56
- STOK $24.50
- AVG Volume (30 Days)
- BMBL 3.5M
- STOK 694.7K
- Earning Date
- BMBL 05-07-2025
- STOK 05-13-2025
- Dividend Yield
- BMBL N/A
- STOK N/A
- EPS Growth
- BMBL N/A
- STOK N/A
- EPS
- BMBL N/A
- STOK 0.88
- Revenue
- BMBL $1,050,969,000.00
- STOK $190,908,000.00
- Revenue This Year
- BMBL N/A
- STOK $44.17
- Revenue Next Year
- BMBL N/A
- STOK $20.00
- P/E Ratio
- BMBL N/A
- STOK $10.88
- Revenue Growth
- BMBL N/A
- STOK 2333.81
- 52 Week Low
- BMBL $3.55
- STOK $5.35
- 52 Week High
- BMBL $12.03
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- BMBL 57.60
- STOK 58.62
- Support Level
- BMBL $5.67
- STOK $9.09
- Resistance Level
- BMBL $6.26
- STOK $9.83
- Average True Range (ATR)
- BMBL 0.25
- STOK 0.61
- MACD
- BMBL -0.03
- STOK -0.03
- Stochastic Oscillator
- BMBL 25.71
- STOK 69.49
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.